- Home
- SCNX vs SLS Comparison
SCNX vs SLS Comparison
Compare SCNX & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCNX
- SLS
- Stock Information
- Founded
- SCNX 2010
- SLS 2012
- Country
- SCNX United States
- SLS United States
- Employees
- SCNX N/A
- SLS N/A
- Industry
- SCNX Other Pharmaceuticals
- SLS Biotechnology: Pharmaceutical Preparations
- Sector
- SCNX Health Care
- SLS Health Care
- Exchange
- SCNX Nasdaq
- SLS Nasdaq
- Market Cap
- SCNX 65.4M
- SLS 69.6M
- IPO Year
- SCNX 2020
- SLS N/A
- Fundamental
- Price
- SCNX $3.90
- SLS $1.33
- Analyst Decision
- SCNX
- SLS
- Analyst Count
- SCNX 0
- SLS 0
- Target Price
- SCNX N/A
- SLS N/A
- AVG Volume (30 Days)
- SCNX 10.8K
- SLS 4.6M
- Earning Date
- SCNX 02-10-2025
- SLS 03-27-2025
- Dividend Yield
- SCNX N/A
- SLS N/A
- EPS Growth
- SCNX N/A
- SLS N/A
- EPS
- SCNX 3.55
- SLS N/A
- Revenue
- SCNX N/A
- SLS N/A
- Revenue This Year
- SCNX $1,085.75
- SLS N/A
- Revenue Next Year
- SCNX N/A
- SLS N/A
- P/E Ratio
- SCNX $1.68
- SLS N/A
- Revenue Growth
- SCNX 166.67
- SLS N/A
- 52 Week Low
- SCNX $3.48
- SLS $0.56
- 52 Week High
- SCNX $44.56
- SLS $1.72
- Technical
- Relative Strength Index (RSI)
- SCNX N/A
- SLS 61.45
- Support Level
- SCNX N/A
- SLS $0.85
- Resistance Level
- SCNX N/A
- SLS $1.60
- Average True Range (ATR)
- SCNX 0.00
- SLS 0.17
- MACD
- SCNX 0.00
- SLS 0.03
- Stochastic Oscillator
- SCNX 0.00
- SLS 64.00
About SCNX Scienture Holdings Inc. Common Stock
Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on providing value to patients and caregivers by offering novel specialty products to satisfy unmet market needs and optimize the prescription journey and patient engagement in the U.S.
About SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.